MedImmune LLC
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 64
- Registration Number
- NCT03001297
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02991911
- Locations
- π¬π§
Research Site, London, United Kingdom
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 42
- Registration Number
- NCT02900157
- Locations
- π―π΅
Research Site, Sunto-gun, Japan
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1453
- Registration Number
- NCT02878330
- Locations
- π¬π§
Research Site, Southampton, United Kingdom
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 301
- Registration Number
- NCT02743117
- Locations
- πΊπΈ
Research Site, Portland, Oregon, United States
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 58
- Registration Number
- NCT02705482
- Locations
- π³π±
Research Site, Amsterdam, Netherlands
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 188
- Registration Number
- NCT02696902
- Locations
- π¬π§
Research Site, London, United Kingdom
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 383
- Registration Number
- NCT02671435
- Locations
- π¬π§
Research Site, Sutton, United Kingdom
Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02669667
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 126
- Registration Number
- NCT02603952
- Locations
- πΏπ¦
Research Site, Welkom, South Africa
Β© Copyright 2024. All Rights Reserved by MedPath